Adaptive Bio, Bristol-Myers Squibb Collaborate on Cancer Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today announced the signing of a collaborative agreement with Bristol-Myers Squibb for the use of Adaptive's technology to discover immunological biomarkers in cancer.

Seattle-based Adaptive Bio will use its immune profiling assay called immunoSeq to identify biomarkers that may be informative about drug response. The next-generation sequencing-based assay characterizes the repertoire of T and B cell receptors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.